Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 125.05 +3.57 (2.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $121.48 | 52 Week High | $108.63 | |||
| Open | $121.79 | 52 Week Low | $71.39 | |||
| Day High | $126.20 | P/E | 69.09 | |||
| Day Low | $121.79 | EPS | $1.81 | |||
| Volume | 1,348,585 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 121.00 +1.91 (1.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $119.09 | 52 Week High | $65.46 | |||
| Open | $120.04 | 52 Week Low | $47.97 | |||
| Day High | $121.20 | P/E | 82.31 | |||
| Day Low | $119.95 | EPS | $1.47 | |||
| Volume | 1,580,290 | |||||
